
ResearchGate

See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/343111510

Effectiveness and Safety of Chloroquine or Hydroxychloroquine as a monotherapy or in combination with Azithromycin in the treatment of COVID-19 patients: Systematic Review and Met...



Effectiveness and Safety of Chloroquine or Hydroxychloroquine as a mono-therapy or in combination with Azithromycin in the treatment of COVID-19 patients: Systematic Review and Meta-Analysis

Ramy Mohamed Ghazy¹, Abdallah Elmaghraby², Ramy Shaaban³, Ahmed Kamal⁴, Hatem Beshir^{5,6}, Amr Moursi⁷, Ahmed Ramadan⁸, Sarah Hamed N. Taha ⁹

Abstract

Many recent studies have investigated the role of either Chloroquine (CQ) alone, Hydroxychloroquine (HCQ) alone, or CQ/HCQ in combination with azithromycin (AZM) in management of the emerging coronavirus. This systematic review and meta-analysis of either published or preprint observational or interventional studies were conducted to assess the cure rate, duration of hospital stay, radiological progression, clinical worsening, need for mechanical ventilation, the occurrence of side effects, and mortality. A search of the online database through June 2020 was performed and examined the reference lists of pertinent articles for in-vivo studies only. Pooled relative risks (RRs), standard mean, of 95 % confidence intervals (CIs) were calculated with the random-effects model. **Results**: The duration of hospital stay was shorter in the standard care in comparison with HCQ group, the standard mean of hospital stay was 0.57, 95% CI, and 0.20-0.94. Overall virological cure, or more specifically at day 4, 10, and 14 among patients exposed to HCQ did not differ significantly from the standard care [(RR=0.92, 95% CI 0.78-1.15), (RR=1.11, 95% CI 0.74-1.65), (RR=1.21, 95%CI 0.70-2.01), and (RR=0.98, 95% CI, 0.76-1.27)] respectively. Radiological improvement or clinical worsening was not statistically

¹ Tropical Health Department, High Institute of Public Health, Alexandria University, Egypt

² Department of Cardiology, Alexandria University, Egypt

³ Department of Instructional Technology and Learning Sciences, Utah State University, USA

⁴ Department of Internal Medicine, Hepatology unit, Alexandria University, Egypt

⁵ Department of Cardiothoracic Surgery, Faculty of Medicine, Mansoura University

⁶ Department of Cardiothoracic Surgery, Egypt Ministry of Health, Alexandria, Egypt

⁷ Department of Neurosurgery, NHS Tayside Trust, UK

⁸ Department of Medical Information and Data Science, DataClin CRO, Egypt

⁹ Department of Forensic Medicine & Clinical Toxicology, Faculty of Medecine, Cairo University, Egypt

different between HCQ and standard care [(RR=1.11, 95% CI 0.64-1.65) and (RR=1.28, 95% CI

0.33-4.99)]. The need for mechanical ventilation (MV) was not significant between the HCQ

group and the standard care (RR= 1.5, 95%CI 0.78-2.89). Side effects were more reported in the

HCQ group than the standard care (RR=3.14, 95% CI 1.58- 6.24). Mortality among HCQ was

not affected by receiving HCQ (RR=3.14, 95% CI 1.58-6.24), meta-regression analysis revealed

that country is a strong predictor of mortality. The duration of hospital stay among the HCQ and

AZM didn't differ significantly from the standard care (standard mean= 0.77, 95% CI 0.46-

1.08). Despite virological cure and need for MV did not differ significantly [(RR= 3.23, 95% CI

0.70-14.97) and (RR=1.27, 95%CI 0.7-2.13)] respectively. Mortality among the HCQ+AZM was

more significantly higher than among the standard care (RR= 1.8, 95% CI 1.19-2.27).

Conclusion: Despite the scarcity of published data of good quality, the effectiveness and safety

of either HCQ alone or in combination with AZM in treating the pandemic of COVID-19 can't

2

be assured. Future randomized control trials need to be carried out to verify this conclusion.

Registration

PROSPERO registration number: CRD42020192084

BACKGROUND

Coronavirus disease-2019 (COVID-19) is a serious health problem caused by the novel Coronavirus (nCOV) or Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)⁽¹⁾. SARS-COV-2 is a member of the Coronavirus family, a family which was previously responsible for Severe Acute Respiratory Syndrome (SARS) in 2002 and Middle East Respiratory Syndrome (MERS) in 2012.⁽²⁾

COVID-19 was emerged by the end of 2019 at Wuhan City in China and was notified by WHO to be a pandemic in March 2020. ⁽³⁾ Till the 19th of July, 2020, 14,444,995 COVID-19 cases and 605,225 deaths were reported worldwide. ⁽⁴⁾

Till now, there is no effective treatment for COVID-19. ⁽⁵⁾ Chloroquine (CQ) was initially reported to be effective against SARS-COV-2 and then Hydroxychloroquine (HCQ) followed. ⁽⁶⁾ SARS-COV-2 is known to bind to human cells via the Angiotensin-Converting Enzyme 2 (ACE 2) receptor. ^(7,8) In-vitro studies showed that CQ and HCQ cause glycosylation of ACE2 receptor making cells to be refractory to SARS-COV-2 infection. ⁽⁸⁾ This makes the drugs possible players in the treatment and even the prophylaxis against COVID-19.

Both drugs have also shown to have immunomodulatory effects. ⁽⁹⁾ HCQ is now broadly used in autoimmune diseases such as Lupus and Rheumatoid Arthritis. ⁽⁹⁾ This makes both drugs potentially effective in reducing the severity of COVID-19 through suppressing the immune system response to SARS-COV-2, which is now thought to be at least partly responsible for the severe forms of the disease. ⁽⁸⁾

The safety of both drugs is also an important issue. Although both drugs are generally well-tolerated, high doses can be associated with severe side effects like myopathy, neuropathy, and cardiomyopathy. (10) Retinopathy is a well-known side effect that is related to prolonged use. (9) Usage of CQ or HCQ in critically ill patients can carry a higher risk of side effects, especially when combined with other drugs that carry a risk of QT interval prolongation increasing the risk of torsade's de points. (11, 12)

In-vivo studies showed contradictory results regarding CQ and HCQ in COVID-19. Firstly, Chinese researchers reported the efficacy of CQ against COVID-19. (13) Then, a French group reported the efficacy of HCQ added to Azithromycin (AZM) in decreasing viral load. (14)

After that, many studies were reported showing no benefit or even harmful effects. (12) Here, we conducted an in-vivo meta-analysis of efficacy and safety of CQ and HCQ in COVID-19.

METHODS

We performed this systematic review in strict compliance with the preferred reporting items of the systematic review and meta-analysis PRISMA checklist ⁽¹⁵⁾. All steps were conducted in concordance with the Cochrane Handbook of Systematic Review and Meta-Analysis ⁽¹⁶⁾.

Inclusion and Exclusion Criteria

Inclusion Criteria

Studies satisfying the following criteria were included:

- Recruited patients with confirmed SARS-COV-2 virus confirmed by Polymerase Chain Reaction (PCR).
- Declared the effect of CQ or HCQ as anti-SARS-COV-2.
- Had a comparator group receiving either standard care, placebo, and other antiviral treatment, with or without a control group.
- Reported any of the following outcomes:
 - o Clinical improvement: the resolution of cough or fever.
 - Virological cure (proportion of virological cure either overall or at certain time day 4,10,
 or 14, or the number of days till virological clearance).
 - Laboratory test improvement (serum ferritin, lymphocyte count).
 - Hospital stay or number of days' till discharge.
 - Radiological improvement.
 - Progression of clinical symptoms.
 - o Need for mechanical ventilation (MV).
 - o Death.

- o Safety of CQ and HCQ; reporting side effects and QT prolongation.
- O Duration of hospital stay, need for MV, virological cure rate, and mortality of the combination (HCQ and AZM).
- No restriction regarding country, race, gender, or age.

Exclusion Criteria

Any study had one of the following criteria would be excluded:

- Published before 2019.
- Conducted in non-human subjects or in vitro studies.
- Abstract-only papers as preceding papers, conference, editorial, and author response and books.
- Studies with data not reliably extracted, duplicate, or overlapping data.
- Any study was written in any language other than English, French, or Chinese.
- Case reports, case series, and systematic review studies were also excluded.

Comparisons

- HCQ or CQ in comparison to standard care.
- HCQ+AZM in comparison to standard care.

Outcomes Conceptualization

Virological Cure Rate

The virological cure in this study includes the number of days until the PCR becomes negative. It includes also the virological cure rate in the days matched between at least two studies. Based on the results, we found matches on days 4, 10, and 14.

Hospital Stay

Hospital stay in this study is the duration of patients stays in hospital measured in days.

Radiological Progression

The radiological progression here includes the number of patients who show progression in their radiological CT results during the period of a study.

Clinical Worsening

By clinical worsening, we mean deterioration of the case during the study's period, or development of complications such as severity progression, or worsening of clinical symptoms.

Need for Mechanical Ventilation (MV)

We mean by the need for MV the percentage of patients who needed respiratory support through MV during a study.

The Occurrence of Side Effects

This includes any side effect that happens from using the studied treatment during a study.

Mortality

Mortality in this study is the percentage of deaths that occur during a study period.

QT Prolongation

In this study, we target specifically the effect of HCQ/CQ/AZ on QT prolongation during a study period.

Data Extraction

A computer literature searches of (PubMed, Google Scholar, Cochrane, Scopus, Web of Science, Segle, VLH, COVID-Inato, COVID-Trial- Clinical Trial.gov) was conducted till June 5th, 2020 using the following keywords (Chloroquine OR Hydroxychloroquine) AND (2019 novel Coronavirus disease OR COVID-19 OR SARS-CoV-2 OR novel Coronavirus infection OR 2019-ncov infection OR Coronavirus disease 2019 OR Coronavirus disease-19 OR 2019-

ncov disease OR COV OR Coronavirus). (Eight independent authors screened the literature search results for relevant studies according to the pre-specified inclusion and exclusion criteria.

All records were collected into an Endnote library to find and delete the duplicates using the "remove duplicating function" with two options is mandatory. All references that had (1) same title and author and published in the same year, and (2) same title and author, and published in the same journal, would be deleted. References remaining after this step were exported to a Microsoft Excel file with essential information for screening. These include the authors' names, publication year, journal, DOI, URL link, and abstract.

The title and abstract screening were done by seven independent reviewers to select papers based on inclusion criteria. Each article was checked by two independent reviewers. Any disagreement was solved by the first author (RG). During the full-text screening phase, all selected articles were downloaded, and the full text was reviewed by two independent reviewers. The decision to include or exclude articles for qualitative and quantitative analysis should be agreed by the two reviewers to pass through. If any disagreement was noticed, the first author was asked to give his decision. The completed data were then thoroughly checked by two reviewers (RMG, AK)

We applied three methods to do manual searching. Firstly, we searched the reference lists of the included articles. Secondly, we performed what is known as citation tracking in which the reviewers track all the articles that cite each one of the included articles. This might involve the electronic searching of databases. Thirdly, similar to the citation tracking, we followed all "related to" or "similar "articles. All excluded records were given exclusion reasons. Manually added research included preprint, and unpublished data if fulfilling the inclusion criteria.

During the data extraction and the quality assessment, in a Microsoft Excel sheet, two reviewers extracted data related to patient characteristics and outcomes (authors, year of publication, country of patients, inclusion or exclusion criteria, when the study was conducted, study's design, sample size, treatment option, dosage and duration, adverse events, primary and secondary outcome). All collected articles and data extracted can be found here (Supplementary Data 1).

Data Analysis

Method of Data Analysis

Data were analyzed using Review Manager Software V5.3 for Windows. For the continuous variables, data were pooled using the mean difference. For the categorical variables, data were pooled using Risk Ratio (RR) with the perspective of 95% Confidence Interval (CI) in the meta-analysis model. In the case of zero frequency, the correction value of 0.1 was used. In the case of significant heterogeneity, we used the random effect model, otherwise, the fixed-effect model was used. Meta-regression analysis was done to examine the impact of age difference on HCQ regimen group mortality RR.

Heterogeneity

Heterogeneity was assessed by the Chi-Square test (X²) and measured by the I-Square test. I-Square (I²) statistic was used for heterogeneity evaluation. Following Cochrane Handbook for Systematic Reviews of Interventions 10, I² was interpreted as follows: "0% to 40%: might not be important; 30% to 60%: may represent moderate heterogeneity; 50% to 90%: may represent substantial heterogeneity; 75% to 100%: considerable heterogeneity. The importance of the observed value of I² depends on (i) magnitude and direction of effects, and (ii) strength of evidence for heterogeneity (e.g. P-value from the chi-squared test, or a confidence interval for

I²). In the case of heterogeneity, DerSimonian and Laird random-effects models were applied to pool the outcomes. Otherwise, the inverse variance fixed-effect model was used. In the case of missing standard deviation (SD), we calculated it from the corresponding 95% confidence interval or the standard error ⁽¹⁷⁾. Forest plots were presented to visualize the degree of variation between studies. In the case of the absence of mean and standard deviation, authors were emailed and asked for the required data, or they were calculated according to the formula mentioned in this research ⁽¹⁸⁾.

Quality Assessment

Quality assessment (QA) of the research depended on the study design. The risk of bias in the individual studies included for meta-analysis was assessed using the Cochrane risk assessment tool in cases of Randomized Control Trials (RCT) ⁽¹⁹⁾, study quality assessment tools for observational study ⁽²⁰⁾, and Robins-1 for Non-Randomized control trial ⁽²¹⁾. The assessment was performed by two independent reviewers (AA, AK, SH) and further checked by two additional reviewers (RG, RS). The risk of bias for non-randomized control trial and observational study is found in the following link (Supplementary Data 2).

Sensitivity Analysis

Sensitivity analysis is known to be an essential part in systematic reviews with metaanalyses to determine the robustness of the obtained outcomes to the assumptions made in the data analysis ⁽²³⁾. We conducted leave ne sensitivity analysis to examine the effect of studies that greatly influence the result, especially by their weight through excluding them from the metaanalysis.

RESULTS

Study Selection Process

A total of 4730 articles were found after searching for 12 different databases. Of this number, 1151 duplicates found by Endnote X8, and 472 were published before 2019. So, they were excluded. Title and abstract included for 3107 papers resulted in the exclusion of irrelevant papers (2394), retracted articles (15), and manually found duplicates (586). Eligibility screening included 112 articles. Finally, 23 papers were eligible, in addition to, 12 papers added manually of which (14) entered in meta-analysis. Figure 1 shows the PRISMA flowchart of the selection process.

Study Characteristics

Out of the fourteen studies entered into the meta-analysis, (2) studies were RCT (1) and non-RCT (3) case-control, and (8) retro or prospective cohort, of which, HCQ arms of the comparative studies have been combined with observational studies for effect size meta-analysis. The studies' sample size ranged from (30 to 1438) participants. Characteristics of studies entered into the systematic review presented in Table 1.

Quality Assessment

Results of quality assessment for studies entered into a meta-analysis using Jadad,
ROBINS-I, and NOS checklists were reported in the summary of the risk of bias has presented in
Figure 2.

Publication Bias

Publication bias assessment was conducted by visual inspection of the funnel plot. (22)




Figure 1. Publication Bias of Randomized control trial




Figure 2: PRISMA flow chart of studies screened and included.

Table 1:

All published studies that reported the effectiveness or safety of Hydroxychloroquine, Chloroquine, or Azithromycin

	Country		No.	Age	Sex	Treatment				
Study	Type of study	Case definition	Patients (Intervention / standard care)	Intervention- standard care)	(Total male percentage)	Intervention Control	Duration (days)	Primary Outcomes	Findings	
	Brazil	Clincally				HCQ 600 bid	22.16			
Borba 2020 (24)	RCT	suspected adults with severe COVID,	81 (41:40)	47.4 ± 13.3	75.3 % males	HCQ 450 bid day 1, 450 OD further 4 days	23 Mar – 5 Apr 2020	Lethality until day 13	39%(high dose) and 15% (low dose)	
Chang 2020 ⁽²⁵⁾		COVID-19 positive	117 (HCQ:66	Total:60.2 ± 14.9	59.5% males	HCQ 400mg bid for 1 d then 200mg bid for 4 d		assess QTc	32.1±25.1ms (HCQ) 35.7±28.9ms (HCQ+AZ)., p=0.66	
	Prospective cohort		HCQ+AZ:51)			HCQ as before +AZ				
Chen.J	China	PCR- confirmed COVID-19	irmed 30 (15:15)	HCQ: 50.5 ± 3.8.	= 3.8. males	HCQ 400 mg/d for 5 d	6 Feb – 25 Feb	PCR conversion One week after hospitalization	86.7% (HCQ) and 93.3%(SC)	
2020(26)	RCT			SC: 46.7 ± 3.6	SC:80% males	SC	2020			
	China			Mean age (SD)	<u> </u>	HCQ 400 od				
Chen. Z 2020 ⁽²⁷⁾	RCT	Covid-19	62 (1:1)	(Intervention 44.1 (16.1) Standard care 45.2 (14.7)	(Intervention 45.2% males Standard care 48.3% males	SC	4 Feb – 28 Feb 2020	Absorption of pneumonia in CT Clinical improvement	80.6% (HCQ) and 54.8% (SC) Shorter duration of cough and fever in HCQ group. Two patients experienced side effect (HCQ). Four paients deterirated in the (SC)	
Chong,	China			51.55± 12.54	63.6% males	Lopinavir/ ritonavir		Developed QT		
2020 ⁽²⁸⁾	Case-series	Covid-19	11			400/100 mg; bid for 14 days+	N/A	prolongation	27.3% developed prolonged QTc	

Gautret, 2020 ⁽²⁹⁾	France Retrospective observational	PCR positive mildly infected Covid-19 patients	80	Median (IQR) 52.5 (42-62)	53.8% males	HCQ 400 mg bid day-1 then 200 mg bid for 2-5) HCQ 200 mg tid for 10 d + AZM 500 mg for 1 d then 250 mg/d for 4 d	3-21 March 2020	Clinical course, viral clearance and hospital stay	Clinical course:81.3% with favorable outcome Viral clearance: 93% had viral clearance at Day8 Hospital stay: mean length of stay of 4.6 days
Gautret, 2020 ⁽²⁹⁾	France Clinical trial	PCR confirmed COVID-19 patients	36 (HCQ:14 HCQ+AZ:6 SC:16)	Total HCQ 51.2 ± 18.7 SC: 37.3 ± 24.0	Total HCQ: 45% males SC: 37.5% males	HCQ 200 tid for 10 d HCQ as before +AZ: loading 500mg then 250mg/d for 4 d SC	Early march-16 march	Virological cure	57.1% (HCQ) , 100% (HCQ+AZ) and 12.5% (SC)
Geleris, 2020 ⁽³⁰⁾	USA Observational	All Hospitalized adult patients with positive COVID-19 infection	1376 (811:565)		HCQ: 58.4% male SC:54.3% male	HCQ 600 mg bid one day then 400 mg/d for 4 days	7 Mar – 8 Apr 2020	Composite of time to intubation or death (time-to-event analysis)	No significant association between HCQ and intubation or death (hazard ratio, 1.04; 95% CI: 0.82–1.32)
Gerard, 2020 ⁽³¹⁾	France	Reports of cardiotoxicity associated with HCQ, CQ, AZM, or LOPI use in COVID- 19.	120	64.3 ± 13.4	76.7%;	HCQ/CQ/A ZM/ LOPI		Cardiac adverse drug reactions	HCQ 86%, AZM 60%. Lopinavir-ritonavir 14% and CQ 2.5%.

Hraiech, 2020 ⁽³²⁾	France Case control	COVID-19 PCR positive ICU patients	45 (HCQ+AZM 17, Lopinavir/ ritonavir 13, SC 15)	HCQ+AZM :60 ± 17 Lopinavir/ ritonavir: 62 ± 13 SC:60 ± 16	HCQ+AZM:88 % males Lopinavir/ ritonavir: 69% males SC:73% males	HCQ 600 mg and AZM 500 then 250 mg/d Lopinavir– ritonavir 800 mg/d	2 Mar – 31 Mar 2020	Viral clearance at day 6 treatment	PCR was negative in 5/13 (38%) from the lopinavir–ritonavir group, 3/17 (1%) from the HCQ–azithromycin group and 2/15 (20%) from the control group.
Macías. 2020 ⁽³³⁾	Spain Retrospective cohort	patients with autoimmune inflammatory diseases with confirmed or suspected COVID 19	(290:432)	56 (45-65)	M HCQ (17.1%)	HCQ vs no HCQ (for autoimmun e disease)	27 Feb – 16 April 2020	Incidence of COVID 19 in patients receiving vs not receiving HCQ	5 cases (1.7%) in those on HCQ vs 5 cases (1.2%) in those not on HCQ
	France			Median (IQR)		HCQ 600 mg/d			
Mahévas 2020 ⁽³⁴⁾	Comparative observational	severe acute respiratory syndrome	173 (84 / 89)	HCQ: 59 (48-67) SC: 62 (54- 69)	HCQ: 77% males SC: 67% males	SC	12 Mar – 31 Mar 2020	the survival rate at day 21 without transfer to ICU	76% (HCQ) and 75% (SC)
Rosenberg,	USA	Lab confirmed COVID-19	1438 (HCQ+AZ:73 5	Median (HCQ+AZ:6 1.4	HCQ+AZ:62 HCQ:58.3 AZ:63.5 SC:49.8	HCQ+AZ HCQ AZ SC	15 Mar –	Mortality	25.7% (HCQ+AZM), 19.9% (HCQ), 10%
2020 ⁽³⁵⁾	Retrospective cohort		HCQ :271 AZ:211 SC:221)	HCQ :65.5 AZ:62.5 SC:64)			28 Mar 2020		(AZM) and 12.7% (SC)
Stroppa, 2020 ⁽³⁶⁾	Italy	COVID-19, Cancer patients	25 Cancer patients,31) 71.64 ± 10.08	80% males in cancer patients, 48% males in	7 days or HCQ 400mg OD	21- February 21, 2020	Mortality	Of the 25 cancer patients, nine (36%) are dead and 16 (64%) arealive, with improvement from

	Case control		Non-cancer patients		Non-cancer patients	alone or AV+HCQ	to March 18, 2020		pneumonia, in the control group of patients hospitalized and treated with the same protocol in the same period, 16.13% are dead and 83.87% are alive $p=0.12$.	
Broek, 2020	Netherlands	Hospitalized and suspected with COVID-	95 patients	Median 65 (min18-	66.3% males	CQ 600mg then 300mg	8-27 March	Assess the degree of CQ induced QTc prolongation in	22 patients (23%) had a QTc interval exceeding 500ms	
	Retrospective observational study	19		max 91)		bid for 5 d	2020	hospitalized COVID-19 patients	hospitalized and treated with the same protocol in the same period, 16.13% are dead and 83.87% are alive p = 0.12.	
Voisin, 2020 ⁽³⁸⁾	France	Hospitalized patients with COVID- 19 pneumonia	50 patients	Median 68 (53-81)	55.2% males	HCQ 600/d for 6 d + AZM 500mg/d for 1 d then 250mg/d for 2-5 d	18 March - 25 March 2020	Effect of HCQ+AZ combination on QTc in case of short term treatment of COVID 19		
	Cohort	рпсипоша				N/A		dealinest of COVID 17		
Yu,2020 (39)	China	Confirmed	OVID-19 in critically ill (48 / 502)	Median (IQR) HCQ: 68	HCQ: 66.7% males SC: 62.2% males	HCQ 200 bid (7-10 days)	February 1, 2020 to April 4 , 2020	Mortality & inflammatory cytokines level	IL-6 reduced from 22.2 (8.3–118.9) pg/ml to 5.2	
Y u,2020 (**)	Retrospective cohort	critically ill adult patients		(60-75) SC: 68 (59-77)		SC				
	China		22 CQ:10	CQ:41.5 (33.8–50.0)	CO:30%	CQ 500 bid for 10 d	January		Virological cure :100% (HCQ) and 91.7%	
Huang, 2020 (b) ⁽⁴⁰⁾	Case control	Confirmed COVID-19 patients	Lopinavir/Rito navir:12	Lopinavir/R itonavir: 53.0 (41.8– 63.5)	CQ:30% Lopinavir/Rito navir: 50%	Lopinavir/ Ritonavir 400/100 mg bid for 10 d	27, 2020 to February 15, 2020	Virological cure, CT scan improvement and hospital discharge at day 14	CT scan improvement:100% (HCQ) and 75% (Lopinavir/Ritonavir) Hospital discharge:100% (HCQ) and 50%	
Magagnoli,2 020 ⁽⁴¹⁾	USA	Lab confirmed COVID-19 hospitalized patients	807 (HCQ: 198 HC+AZ:214 SC:395)	Median HCQ: 71 (62–76.8),	HCQ: 97% HCQ+AZ :95.3% SC: 95.2%	HCQ 400/d for 5 d	March 9, 2020 and April 29, 2020	Mortality & mechanical ventilation	p = 0.009, but HCQ+AZM aHR, 1.31; 95% CI, 0.80–2.15; p = 0.28. compared to SC Mechanical ventilation: HCQ aHR, 1.19; 95%	

	Retrospective cohort			HCQ+AZ :68 (59–74) SC: 70 (59– 77)		HCQ 422/d + AZM for 5 d			1.09; 95% CI, 0.72–1.66; p = 0.69, compared to SC
	USA					HCQ+AZ M			
Ramireddy, 2020 ⁽⁴²⁾	Case-series	COVID-19 Confirmed/su spected patients	98 (27 AZM - 10 HCQ - 61 AZ+ HCQ)	62.3 ± 17	61% males	HCQ 400 bid on day1 then 200 bid on days 2 to 5 AZM either 500mg daily or 500 mg on day1 followed by 250mg daily on days 2-5.	1 February 2020 to 4 April, 2020	QT prolongation	Significant prolongation in men (12% of patients) reached critical QTc prolongation. Changes in QTc were highest with the combination group compared to either drug alone, with many-fold greater prolongation with the combination vs. azithromycin alone (17±39 vs. 0.5±40 ms, p=0.07)
Barbosa, 2020 ⁽⁴³⁾	USA Retrospective	PCR positive COVID-19 patients	63 (32/ 31)	HCQ: 61.8 ± 15 SC:63.7±15.	HCQ: 46.9% males SC: 71% males	HCQ 400mg bid for 1-2 days then 200- 400mg/d for 3-4days	15 March 2020 -31 March 2020	Mortality rate	12.9% (HCQ) and 3.13% (SC)
	cohort								
Mallat,2020 ⁽⁴	UAE	Hospitalized adult patients with confirmed	34 (23/11)	HCQ: 33 (31-48) SC: 41 (30-	HCQ: 73.9% males SC: 72.7%	HCQ 400 mg bid for 1 day, then 400 mg/d for 10 days.	1 March - 25 March,	The time to SARS-CoV-2 negativity	17(13-21) days HCQ and 10(4-13) days SC
	Retrospective cohort	SARS-CoV-2 infection		55)	males	SC	2020		
Huang,	China	Confirmed COVID-19 cases	OVID-19 (197/ 176	CQ: 43.8 ±13.1	CQ:49%	HCQ 500/d	7 Feb-8	Median Time to undetectable viral RNA	3(3-5) HCQ and 9(6-12) SC.
Huang, 2020 ⁽³⁾	Prospective Observational			SC:45.6±13.	SC:45%	SC	March 2020		

Feng, 2020 ⁽⁴⁵⁾	China Retrospective cohort	Confirmed COVID-19 cases	50 (25/25)	median CQ: 51 (41 - 62) SC: 46 (38 - 67)	Male: (50.4%)	CQ 500mg bid	Jan 17- Feb. 28 2020	lry outcome: development of severe pneumonia	None of patients treated with chloroquine developed severe pneumonia, though without significance (difference, 12.0%; 95% CI, -3.5% to 30.0%; P =0.074)
Mathian,202 0 ⁽⁴⁶⁾	France	SLE with COVID-19	17 patients on HCQ	53.5 (26.6– 69.2)	23.5% males	НСО	29 March- 6 April	Clinical curse	Admitted to hospital (82%); needed O2 therapy (64.7), ICU admission (41%) Respiratory complications: ARDS (29%) RF (65%) Pneumonia (76%) Acute renal failure (17.6%),
C	Case series					N/A	2020		hemodialysis (11.8%) Discharge (36%), Death (14%), remained in hospital (50%)
Tang 2020 ⁽⁴⁷⁾	China	patients hospitalized with PCR confirmed mild to moderate COVID-19	150 (75/75)	14.1. 42 SC 44.1 ± M	HCQ: Males= 42(56%), SC Males= 40 (53%)	HCQ 1200 for 3d then 800/d for 14-21 d	11 to 29 February	Rate of viral negative conversion at 28 days	(56/75 (74.6%) in SC and 53/75 (70.6%) in HCQ) negatively converted before 28 days
	RCT					SC			
Carlucci, 2020 ⁽⁴⁸⁾	USA	PCR positive COVID-19 patients	COVID-19 Z:411	Zinc+HCQ+ AZ: 63.19 ± 15.18 HCQ+AZ: 61.83 ± 15.97	Zinc+HCQ+A Z:64.3% males HCQ+AZ:61.4 % males	HCQ 400 mg/d for 1 d then 200 mg bid for 5d +AZ 500 mg/d for 5 d+ zinc sulfate 220 mg bid for 5 d	2 March 2020 to 5 April 2020	Effect of adding zinc to HCQ and AZM	The addition of zinc sulfate did not impact the length of hospitalization, duration of ventilation, or ICU duration.
	retrospective observational					The same dose as in the other group but without zinc			
Singh, 2020 ⁽⁴⁹⁾	USA	Confirmed COVID-19 patients	1820 (910 /910)	HCQ:62.17 ±16.81 SC:62.55±1 7.62)	HCQ: 53.96% males SC: 54.94% males	HCQ (dose not mentioned)	20 January, 2020, to 1 May, 2020	Mortality 30-Day & Need for mechanical ventilation	Mortality: 11.34% (HCQ) and 11.98% (SC) Mechanical ventilation: 5.05% (HCQ) and 6.26% (SC)

	Retrospective cohort								
Regina, 2020 ⁽⁵⁰⁾	Switzerland	laboratory confirmed	200	70.0 years [IQR 55.0- 81.0]	Male, 60%		from March 1	Need for mechanical ventilation (MV)at day 14	HCQ: (31.2%) Remdisivir: (100%)
2020	Retrospective cohort	SARS-CoV-2 patients					to March 25, 2020		Protease inbititors: (31%) Tocilizumab:(82%)
Membrillo,2 020 ⁽⁵¹⁾	Spain	laboratory confirmed SARS-CoV-2 patients	166 (123 / 43) 83 patients had mild clinical picture at admission, 48 moderate and	(16.2) ma SC: 68.7 No	HCQ: 61.8% males Non HCQ: 62.8% males	Loading dose of HCQ 800 mg + 400 mg, followed by maintenanc e dose of 400 mg/d	-NA	Mortality	48,8 % of patients not treated with HCQ died versus 22% in the group of HCQ (p=0,002). HCQ increased the mean cumulative survival in the mild moderate & severe group to 1,8,1.4, 1,6 times respectively but difference was statistically significant in the mild group.
	Observational Cohort		35 severe.		400 mg /d SC				
Log 2020 ⁽⁵²⁾	South Korea	Confirmed	72 (LPV/r:45 HCQ:27	Median (IQR) LPV/r: 39	LPV/r: 44.4% HCQ:44.4%	LPV/r: 400/100 mg/d bid	February 21, 2020	Compare clinical outcomes of both treatments	Disease progression (HCQ) 44% and (LPV/r)
Million, 2020 ⁽⁵³⁾	Retrospective cohort	COVID-19 patients		(24–56) HCQ: 37 (24–53)		HCQ:400m g/d	to March 21,2020		18%
	France	ngn ::				HCQ 200 mg tid for 10 d + AZM 500	March		
	Retrospective cohort	PCR positive COVID-19 patients	1061	43.6 ± 15.6	46.4% male	mg on day 1 followed by 250 mg/d for 4 d	3rd to March 31st	Death, clinical worsening and viral shedding persistence (> 10 days).	91.7% had good clinical outcome and virological cure, 4.4% had viral shedding persistence and 0.75% died
Okour, 2020 ⁽⁵⁴⁾	USA Non RCT	Confirmed COVID-19 patients	36 Patient	Not provided	Not provided	HCQ +/- AZM	March 2020	probability of negative- PCR in patients.	odds of positive-PCR decrease by 53% for each unit increase in HCQ log-concentration. Similarly, the odds decrease by 61%, and by 12% for each day increase, and for azithromycin co-treatment, respectively.

Saleh, 2020 ⁽⁵⁵⁾	USA Prospective cohort	Confirmed COVID-19 patients	201 CQ:10 HCQ: 191 from the previous sample 119 received AZ	58.5±9.1	Males (57.2%)	CQ 500 mg bid for 1 d then 500 mg/d for 4 d or HCQ 400mg bid for 1 d then 200 mg bid for 4 d The same doses as before + AZM 500 mg/d for 5 days	March 1- 23,2020	Assess QT prolongation resulting in Torsade de pointes	440.6±24.9 ms (HCQ/CQ) and 439.9±24.7 ms (HCQ/CQ + AZM) (P=0.834)
Chorin,2020 (56)	USA Retrospective cohort	COVID-19 patients	251 patients	64±13	75% males	HCQ 400 mg bid for 1 d then 200 mg bid for 4 days. + AZM was 500 mg/d for 5 d		Assess the change in QTc	QTc >500 ms, occurred in 23% of patients.

AZ: azithromycin; HCQ: hydroxychloroquine; CQ: cholooroquine; SC: standard care; PCR: Polymerase chain reaction; ICU: intensive care unit; CT: computed tompgraphy; IQR: interquartile range; RCT: randomized control trial; LPV/r :Lopinavir/ritonavir

Hydroxychloroquine Versus Standard Care

Fever

A total of three studies that evaluated body temperature normalization after HCQ therapy; Huang et al,⁽³⁾ reported that body temperature returned normal after a geometric mean (coefficient variation), 1.2 (53.5) among HCQ group versus 1.9 (110.0) among non HCQ (P= 0.0029), while J.chen et al, ⁽¹³⁾ reported that patients' temperatures returned to normal at approximately the same rate in both groups. (Median 1, IQR 0-2 for HCQ and Median 1, IQR 0-3 for no-HQR). Z. Chen et al,⁽²⁷⁾ reported that the duration of fever was shorter in the HCQ group (mean 2.0±0.2) than in the non-HCQ group (mean 3.1±1.5).

Cough

Z. Chen et al, $^{(27)}$ reported that 15 of 31 (48.39%) of the control patients and 22 of 31 (70.97%) intervention patients had reported cough resolution. This difference was statistically significant P= 0.0016

Laboratory Test Improvement

Two studies evaluated the change in laboratory test after exposure to HCQ, first Mallat et al, (44) reported that median lymphocyte count at day 7 was 1870 (1115-2625) compared to its baseline 1890 (1430-2230) in the control group, while it was 1650 (980-1950) at day 7 in the intervention group compared to its baseline level 1650(980-1950). Additionally, median serum ferritin level day 7 was 398 (52-1030) compared to its baseline 292 (33-1085) in the control group, while it was 249 (130-614) at day 7 in the intervention group compared to its baseline level 165 (63-320). Barbosa et al, (43) reported that change in Neutrophil to Lymphocyte Ratio was higher in HCQ (9.55±21.5) versus standard care (1.58±6.26) but this increase was not

significant. Similarly, the change in absolute lymphocyte count was not statistically significant between both groups (-0.61 ± 0.52 of HCQ group vs -0.61 ± 0.38 standard care).

Hospital Stay

The duration of the hospital stay of patients of the standard care group was significantly shorter than in the HCQ/CQ group (summary std. mean difference was 0.57, CI, 0.20-0.94). Of the four included studies, three studies favored the standard care with std. mean difference ranging from (0.50-1.19). The heterogeneity of the included studies was as follows (I^2 =92%, p <0.01). (Figure 3). In the sensitivity analysis, M. Huang, 2020 contributed most to heterogeneity. Excluding this study made the overall effect relatively higher (Z=12.33, P<0.000) and the test of heterogeneity was not significant (P = 0.54, P=0%) (Figure 4)




Figure 3. Duration of hospital stay of HCQ versus standard care




Figure 4. Sensitivity analysis by leave one out sensitivity analysis.

Virological Cure

Time to negative PCR. Four studies evaluated the time to negative PCR after administration of HCQ or CQ One study proved that intervention was more effective (Std. mean=-163, 95% CI -1.86 - -1.39), however, the pooled Std. mean of these studies indicated

there were no significant differences between the HCQ group and the standard care group in terms of the time for PCR to turn negative (RR: 0.05, 95% CI, -1.32-1.42). The measured heterogeneity was statistically significant I2=98%, P < 0.01. (Figure 5). Sensitivity analysis revealed that M. Huang, 2020 contributed most to heterogeneity. By the Exclusion of this study, the heterogeneity between the rest of the studies was insignificant (P=0.45, I²=48%). Moreover, pooled std. mean turned to be significantly shorter in standard care groups (Z=2.32, P=0.02) (Figure 6).




Figure 5. Forest plot for pooling risk ratios regarding the time to a negative PCR.




Figure 6. Sensitivity analysis by leave one out sensitivity analysis.

Virological cure rate. To get more insight over the virological cure, we were able to find two studies that analyzed the virological cure rate on day 4, two studies analyzed it on day 10, and three analyzed it on day 14. There were no differences between the HCQ group and the standard care group [(RR: 1.11, 95% CI, 0.26-4.69), (RR: 1.21, 95% CI, 0.70-2.10), and (RR: 0.98, 95% CI, 0.76-1.27)] (Figure 7-9). The heterogeneity of the three analysis were ($I^2 = 85\%$, P = 0.01, $I^2 = 95\%$, P < 0.01, and $I^2 = 85\%$, P < 0.01) respectively. The comparison of the

virological cure rate at day 14 was subjected to leave one out sensitivity analysis. There was substantial heterogeneity between studies at all stages of the test. However, M. Huang, 2020 contributed to most of the heterogeneity (Figure 10).



Figure 7. Forest plot for pooling risk ratios regarding virological cure rate on day four



Figure 8. Forest plot for pooling risk ratios regarding virological cure rate on day 10.




Figure 9. Forest plot for pooling risk ratios regarding virological cure rate on day 14.




Figure 10. Leave one out sensitivity analysis.

The overall virological cure was not statistically significant between the intervention group and the standard care. The pooled RR was 0.91, 95% CI = 0.79-1.05). The heterogeneity of the studies was as follow $I^2 = 67\%$, P = 0.03 (Figure 12). In the sensitivity analysis, P. Gautret, 2020 contributed to most of the heterogeneity. By exclusion of this study, the heterogeneity was not significant between the rest of the studies (P = 0.26, P = 0.26).




Figure 11. Forest plot for pooling risk ratios regarding the overall virological cure rate




Figure 12. Sensitivity Analysis

Radiological Improvement

Three studies evaluated the radiological improvement differences between the HCQ group and the standard care group. Only one study reported better radiological improvement of the standard care (OR=1.47: 95% CI, 1.02-2.11). The HCQ group didn't statistically significantly differ from the standard care group (RR: 1.11, 95% CI, 0.74-1.65) (Figure 13). The heterogeneity between studies was not significant (P=0.16, I2=45%). Sensitivity analysis showed

that Z Chen, 2020 contributes most of the heterogeneity. By exclusion of this study, the I² index approached 0% (Figure 14).




Figure 13. Forest plot for pooling risk ratios regarding radiological improvement.

	HCC	Q	Control			Risk Ratio	Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Rand	om, 95% CI	
J.Chen 2020	5	15	7	15	20.1%	0.71 [0.29, 1.75]			
M.Huang 2020	27	50	12	21	79.9%	0.94 [0.60, 1.48]	-	-	
Z Chen 2020	25	31	17	31	0.0%	1.47 [1.02, 2.11]			
Total (95% CI)		65		36	100.0%	0.89 [0.60, 1.34]			
Total events	32		19						
Heterogeneity: Tau² =	0.00; Ch	$i^2 = 0.3$	1, df = 1 (P = 0.5	8); I² = 09	6	0.01 0.1	1 10	100
Test for overall effect:	Z = 0.55	(P = 0.5)	58)				Favours [Standard Care]		100

Figure 14. Leave one sensitivity analysis.

Worsening of Clinical Symptoms

Five studies evaluated the differences between the HCQ or CQ group and the standard care group in terms of clinical worsening. The meta-analysis showed there were no differences between the HCQ group and the standard care group regarding the worsening of clinical symptoms (RR: 1.28, 95% CI, 0.33-4.99). The heterogeneity of the studies was not significant $P = 0.07 \& I^2 = 54\%$ (Figure 15). Sensitivity analysis revealed that M. Huang, 2020 contributed most to heterogeneity. By exclusion of this study, the heterogeneity of studies was not significant ($P = 0.29, I^2 = 19\%$) (Figure 16).




Figure 15. Clinical worsening of the hydroxychloroquine versus the standard care




Figure 16. Leave one Sensitivity Analysis

Need for Mechanical Ventilation

The need for MV was reported in five studies in both the HCQ group (118/1395) and the standard care group (156/1617). Two studies reported more need for mechanical ventilation among the standard care group, (rang of individual RR is 1.03-18.17, 95% CI). In the analysis, there was no significant difference between both groups (summary RR = 1.50, 95% CI, 0.78-2.89) as shown in (**Figure 17**). The test of heterogeneity was statistically significant I²=81%, P=0.001. Upon performing leave one out sensitivity analysis, there was a substantial heterogeneity at all stages of the test. However, ES. Rosenberg, 2020 contributed most to heterogeneity between studies. By exclusion of the study, the heterogeneity was insignificant (P=0.08, I²=61%) (Figure 18).




Figure 17. Need for mechanical ventilation of the hydroxychloroquine versus standard care




Figure 18. Leave one sensitivity analysis

Side Effects

Three studies addressed side effect of HCQ revealed that intervention group witnessed greater side effects than the standard care (27/116) and (9/126) respectively, this difference was statistically significant (pooled RR= 3.14, 95% CI: 1.58-6.24). The heterogeneity of the studies was not significant (I2=0%, P=0.79) (Figure 19).




Figure 19. Side effects of the hydroxychloroquine versus the standard care

QT Prolongation

Many studies have evaluated the effect of HCQ in inducing QT prolongation; Chong et al. demonstrated that 45.5% of patients exposed to HCQ developed QT prolongation. On the same vein, Broek et al, (37) noticed that 23% of CO patients developed significant OT prolongation (>500msec). Voisin et al, (38) reported that of 50 patients treated with HCQ+AZM; 6 patients stopped the treatment due to significant QT prolongation, and 8 patients and 38 patients (76 %) presented short term modifications of QTc duration (meaning > 30 ms). The same figure was reported by Ramireddy et al. (42) and Saleh et al., (55) who reported that there is no difference regarding QT prolongation between patients treated with CQ or HCQ. Moreover, combination with AZM increased the risk of QT prolongation as (470.4±45.0 ms) versus monotherapy (453.3±37.0 ms), P=0.004. This increase in QT prolongation was incriminated in discontinuation of treatment in 3.5% of the studied patients. On the other hand, Rosenberg et al. (35) reported a lower incidence of QT prolongation among patients treated with a combination of HCQ+AZM versus HCO alone (11.0% vs 14.4%) respectively. Finally, Chang et al., (57) reported that 17.9% of patients treated with HCQ± AZN had QT prolongation > 500 m-second. The prolongation of QT after administration of HCQ+AZM or HCQ alone was not significantly different.

Mortality

Mortality was addressed in 8 studies and controversial results were seen. B. Yu et al,⁽³⁹⁾ FJ and Membrillo et al ⁽⁵¹⁾ showed that there is more mortality in the standard care groups in comparison to the HCQ. While, Rosenberg et al and Magagnoli et al,⁽⁴¹⁾ showed that there was more mortality in those who did receive HCQ. It is worthy to mention that, 'among the 20 patients included in the study of Guatret et al, ⁽¹⁴⁾ 6 patients were on AZM. In the analysis there was no significant difference between the two groups with RR of 0.99, 95% CI 0.61, 1.59 as

shown in Figure 20. Leave one out sensitivity analysis revealed a considerable heterogeneity at all stages of the studies. All studies nearly equally contributed to the overall heterogeneity. Hence, meta-regression was needed to underline the possible effect of covariates. The risk of mortality was regressed considering mean or median age, country, percentage of male patients, and severity of illness as regressors. Age was not a significant predictor (P=0.323) as the mean or median age was above 60 years across all selected studies except for P. Gautret, et al., study (14) in which the median age of the participant was 45 years. Moreover, the severity of illness was not significant (P=0.105) as the patients in almost all selected studies were hospitalized with varied clinical status except for B. Yu, et al, (39) in which the patients were all critically ill. Interestingly, the country of the study was a significant predictor for the risk of mortality at two levels (France and USA) setting for China (B. Yu, 2020) as a reference country. Switching from Chinese to French studies increases the relative risk of mortality in HCQ groups by 7.28 times (P=0.001) concerning SC groups. Similarly, switching from Chinese to American studies increased the relative risk of mortality in HCQ groups by 4.29 times (P=0.005). By Metaregression, the overall heterogeneity of selected studies was not significant (0.243, $I^2=22\%$). Publication bias of included study is presented in (Figure 21).




Figure 20: Mortality in the hydroxychloroquine vs standard care group




Figure 21. Funnel plot of included studies highlighted mortality of HCQ regimen

Hydroxychloroquine and Azithromycin Combination Versus Standard Care Duration of Hospital Stay

The duration of hospital stay in case of treatment with (HCQ + AZM) combination versus standard care was reported in two studies. In the analysis, we found a significant difference between both groups where the (HCQ + AZM) combination group had the longer mean hospital stay among COVID 19 treated patients. The pooled Std. mean was 0.77, 95% CI, 0.46-1.08). The heterogeneity was statistically significant, P < 0.01, $I^2=92\%$ (Figure 22).




Figure 22. Duration of hospital stay of HCQ+AZM versus standard care Virological Cure Rate

Two studies reported the virological cure of HCQ+AZM combination versus standard care. The archived virological cure rate of HCQ and AZM combination (9/23) did not differ significantly from the standard care (4/31) (RR = 3.24, 95% CI, 0.71-14.74). The heterogeneity of the study was not significant P=0.12 I²= 58% (Figure 23).




Figure 23. The virological cure rate of HCQ and azithromycin versus standard care

Need for Mechanical Ventilation

Four studies evaluated the need for MV in both (HCQ+AZM) group (186/1627) and the standard care group (153/1389) and found no significant difference between both groups (RR = 1.27, 95% CI, 0.76-2.13). The heterogeneity of the studies was as follows I^2 = 88%, P < 0.01 (Figure 24). Leave one out sensitivity analysis was performed, ES. Rosenberg, 2020 contributed most to overall heterogeneity. By exclusion of this study, the heterogeneity between other studies was insignificant (P=0.82, I^2 =0%) (Figure 25).




Figure 24. Need for mechanical ventilation of HCQ and AZM versus standard care.




Figure 25. Leave one sensitivity analysis.

Mortality

Meanwhile comparing mortality in patients taking HCQ and AZM with those receiving standard care was addressed in 4 studies, two of them showed more mortality in the intervention group versus standard care group and the analysis there was no significant difference between the two groups with RR of 1.81, 95% CI, and 0.7-14.97 (Figure 26). Leave one out sensitivity test was

performed. S. Singh, 2020 contributed most to the overall heterogeneity. By exclusion of this study, the heterogeneity between other studies was insignificant (P=0.71, I2=0%) (Figure 27).




Figure 26. Mortality of Hydroxychloroquine and Azithromycin versus standard care.




Figure 27. Leave one sensitivity analysis.

DISCUSSION

Based on the finding of this meta-analysis, the treatment of COVID-19 patients with HCQ was associated with a longer duration of hospital stay, whether or not AZM was included in the treatment regimen. Regarding the difference in viral clearance between HCQ and standard care, time to negative conversion was not statistically different between the two groups (HCQ and standard care). Similarly, virological cure at either day 4, day 10, or day 14 was not different between both groups. It is worthy to mention that adding AZM to HCQ did not affect the cure rate versus standard care. Generally, exposure to HCQ alone or in combination with AZM wasn't associated with the need for mechanical ventilation. Furthermore, neither clinical worsening nor radiological improvement of the studied patients was changed concurrently with exposure to HCQ. Side effects were more encountered if patients were exposed to HCQ, finally, the mortality of the HCQ group was not different from that of standard care. The country of residency was a significant predictor of mortality outcomes. The alarming finding was that the standard care had reported lower numbers of mortalities if they were compared to the AZM and HCQ combination group.

Fever and Cough

Resolution of respiratory symptoms and fever is one of the symptoms-based indicators of disease recovery. In this study, we evaluated the recovery of these two symptoms after exposure to HCQ. ⁽⁵⁸⁾ Huang et al, and Z. Chen et al demonstrated that patients treated with CQ recover from fever faster than those on standard care, however, J.Chen did not report any significant difference between both groups in the resolution of fever. Z. Chen et al reported a more significant resolution of cough among patients exposed to HCQ. Due to insufficient data, we did not conduct a meta-analysis.

QT Prolongation

Abnormal myocardial repolarization results in QT interval prolongation. The normal QT interval is 470 ms in females, and 450 ms in males. ⁽⁵⁹⁾ Among patients treated with HCQ, QT prolongation was identified in 23%-45.5%. ^(28, 37). About 12% of patients on AZM and HCQ stopped treatment due to significant QT prolongation. It is important to notice that there is no difference in the incidence of drug-induced QT prolongation by CQ or HCQ. A combination of HCQ and AZM increases the risk, however, Rosenberg et al, reported a lower occurrence of QT among patients received this combination versus standard care. ⁽³⁵⁾

Duration of Hospital Stay of HCQ ± AZM versus Standard Care

Adoption of either CQ/HCQ alone or in combination with AZM did not significantly shorten the duration of hospital stay. Patients on the standard care stay shorter in the hospital either if they compared to patient received CQ/HCQ (standard mean difference 0.54, 95% C10.20-0.94) or HCQ+AZM (standard mean difference 0.77, 95%CI 0.46-1.08) the reported heterogeneity of the CQ/HCQ study was 92% that dropped to 0% if the study of Huang was removed. While the heterogeneity of HCQ+AZM analysis was 81%

Virological Cure Rate of CQ/HCQ ±AZM Versus Standard Care

In the current research, the achieved cure rate of HCQ (day 4, 10, and 14), and time to negative conversion among the HCQ group were not statistically different from the standard care. It is worthy to mention that, the term standard care was not firmly defined in each study, this may represent a source of prescription bias. Another important finding was that the pooled standard mean difference included the paper published by Huang et al, ⁽³⁾ this research resulted in significant heterogeneity in many outcomes especially time till virological cure. When we adopted the leave one sensitivity analysis the time to negative conversion became significantly shorter in the control arm.

Similarly, the virological cure rate of HCQ and AZM combination did not significantly differ from the cure rate of the standard care. This finding is similar to the result reported by Shamshirian et al,.⁽⁶⁰⁾ In this study they included the study conducted by Maganogli et al, ⁽⁴¹⁾ in evaluating the effectiveness of HCQ+AZM combination. By reviewing this article, we found that the authors did not address the effectiveness of this combination versus standard care. ⁽⁴¹⁾.

Radiological Improvement and Clinical Worsening

Treatment with HCQ did not provide any additional benefit in terms of radiological improvement or clinical worsening versus the standard care. We included three published articles in this analysis of the impact of HCQ on radiological improvement and five articles evaluating the effect of CQ/HCQ on clinical worsening. The heterogeneity of both analyses was 45% and 54% respectively.

Need for Mechanical Ventilation of AZM+HCQ versus Standard Care

The need for mechanical ventilation was evaluated in our study in case of treatment with HCQ and (HCQ+AZM) combination compared to the standard treatment group. In our study, we included 5 studies in the comparison between HCQ and standard care, we analyzed the effect of (HCQ+AZM) combination in 4 studies and in both analyses no significant difference was found indicating that the use HCQ either alone or in combination with AZM for treatment of COVID 19 did not reduce the need for MV. Our results are in agreement with Shamshirian et al. ⁽⁶⁰⁾ who published an MA of two studies addressing the need for MV among HCQ and standard care.

Side Effects

In this meta-analysis, we included three published pieces of research that address the reported side effects of HCQ treatment. Patients on HCQ treatment had a higher risk of

experiencing side effects, (pooled RR=3.14, 95% CI 1.58-6.24) with I² of 0%. The reported side effects were diarrhea, headache, rash, elevated transaminases, fatigue, and anemia.

Mortality HCQ and AZM

In the current research, the Mortality rate of HCQ alone did not significantly differ from the cure rate of standard care. This was similar to what is reported by Shamshirian et al, ⁽⁶⁰⁾who almost included the same studies in his meta-analysis. The heterogeneity of this analysis was high so we conducted a sensitivity analysis to identify the source of heterogeneity. All studies contributed nearly equal to the reported heterogeneity, so we carried out meta-regression analysis. In Meta-regression analysis, the heterogeneity dropped to 22% and we identified that country was a strong predictor of mortality. One of the alarming findings was that the mortality of the HCQ and AZM was significantly higher than the standard care (pooled RR= 1.81, 95% CI 1.19-2.77). The heterogeneity of this analysis was (I²= 71%).

Limitation

Our analysis must be interpreted in the context of the limitations of the available data; despite the huge number of published articles during the COVID-19 pandemic, many of these studies lack a good quality and may contain inconsistent results. In fact, there is an urgent need for high-quality randomized control trials that address the issue of HCQ treatment.

Consequently, we depended on our analysis of the few published or even cited preprints. Moreover, we included many observational studies due to the scarcity of randomized control trials. It is well established that observational studies cannot discover causality. This fact also contributed to the highly found heterogeneity of analysis especially for the study of Haung (2020). (3) After leaving one sensitivity analysis the heterogeneity drops to acceptable value in many outcomes. Another important source of bias in patient selection bias; as some studies did

not classify patients according to their disease's severity. This source of bias may significantly affect the course of illness. Differences in HCQ and AZM in dose, duration of treatment, and route of administration may also affect the consistency of our results.

Conclusion

HCQ prolonged the duration of hospital stay and did not increase the overall virological cure or more specifically on days 4, 10, or 14. In addition, it did not affect duration till conversion to negative PCR, need for MV, radiological progression, clinical worsening of the disease, or death. Furthermore, treatment with AZM and HCQ did not affect the virological cure, the need for MV. However, it increased the duration of hospital stay and mortality. Future randomized clinical trials are needed to confirm these conclusions.

Conflict of Interest

No conflict of interest

References

- 1. Wang L, Wang Y, Ye D, Liu Q, 2020. Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. International Journal of Antimicrobial Agents.55(6), 105948 DOI: https://doi.org/10.1016/j.ijantimicag.2020.105948.
- 2. de Wit E, van Doremalen N, Falzarano D, Munster VJ, 2016. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol.14(8), 523-34.
- 3. Huang M, Li M, Xiao F, Pang P, Liang J, Tang T, Liu S, Chen B, Shu J, You Y, 2020. Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19. National Science Review.
- 4. World meter. COVID-19 CORONAVIRUS PANDEMIC 2020 [updated July 19, 2020, 09:16 GMT. Available from: https://www.worldometers.info/coronavirus/.
- 5. Lotfi M, Hamblin MR, Rezaei N, 2020. COVID-19: Transmission, prevention, and potential therapeutic opportunities. Clinica chimica acta; international journal of clinical chemistry.508, 254-66 DOI: 10.1016/j.cca.2020.05.044.
- 6. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, Labella A, Manson DK, Kubin C, Barr RG, et al., 2020. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med.382(25), 2411-8.
- 7. Devaux CA, Rolain J-M, Raoult D, 2020. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. Journal of Microbiology, Immunology and Infection.53(3), 425-35 DOI: https://doi.org/10.1016/j.jmii.2020.04.015.
- 8. Pahan P, Pahan K, 2020. Smooth or Risky Revisit of an Old Malaria Drug for COVID-19? Journal of neuroimmune pharmacology: the official journal of the Society on NeuroImmune Pharmacology.15(2), 174-80 DOI: 10.1007/s11481-020-09923-w.
- 9. Schrezenmeier E, Dörner T, 2020. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol.16(3), 155-66.
- 10. Gevers S, Kwa MSG, Wijnans E, van Nieuwkoop C, 2020. Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. S1198-743X(20)30283-4 DOI: 10.1016/j.cmi.2020.05.006.
- 11. Juurlink DN, 2020. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. CMAJ: Canadian Medical Association journal = journal de l'Association medicale canadienne.192(17), E450-E3 DOI: 10.1503/cmaj.200528.
- 12. Pastick KA, Okafor EC, Wang F, Lofgren SM, Skipper CP, Nicol MR, Pullen MF, Rajasingham R, McDonald EG, Lee TC, et al., 2020. Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). Open forum infectious diseases.7(4), ofaa130-ofaa DOI: 10.1093/ofid/ofaa130.
- 13. Chen J, LIU D, LIU L, LIU P, XU Q, XIA L, LING Y, HUANG D, SONG S, ZHANG D, 2020. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). Journal of Zhejiang University (Medical Science).49(1), 0-.
- 14. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, et al., 2020. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents. 105949- DOI: 10.1016/j.ijantimicag.2020.105949.

- 15. Moher D, Liberati A, Tetzlaff J, Altman DG, 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of internal medicine.151(4), 264-9.
- 16. Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions: John Wiley & Sons; 2011.
- 17. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N, 2006. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of clinical epidemiology.59(1), 7-10.
- 18. Wan X, Wang W, Liu J, Tong T, 2014. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC medical research methodology.14(1), 135.
- 19. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savović J, Schulz KF, Weeks L, Sterne JA, 2011. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Bmj.343, d5928.
- 20. National Institute of Health. Study Quality Assessment Tools [Available from: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools.
- 21. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, 2016. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. bmj.355.
- 22. Egger M, Smith GD, Schneider M, Minder C, 1997. Bias in meta-analysis detected by a simple, graphical test. Bmj.315(7109), 629-34.
- 23. Bown MJ, Sutton AJ, 2010. Quality control in systematic reviews and meta-analyses. Eur J Vasc Endovasc Surg.40(5), 669-77 DOI: 10.1016/j.ejvs.2010.07.011.
- 24. Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, Mourão MPG, Brito-Sousa JD, Baía-da-Silva D, Guerra MVF, 2020. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA network open.3(4), e208857-e.
- 25. Chang D, Saleh M, Gabriels J, Ismail H, Goldner B, Willner J, Beldner S, Mitra R, John R, Epstein LM. Inpatient Use of Ambulatory Telemetry Monitors for COVID-19 Patients Treated with Hydroxychloroquine and/or Azithromycin. J Am Coll Cardiol. DOI: 10.1016/j.jacc.2020.04.032
- 10.1016/j.jacc.2020.04.032..
- 26. Jun C, Danping L, Li L, Ping L, Qingnian X, Lu X, Yun L, Dan H, Shuli S, Dandan Z, et al., 2020. A Pilot Study of Hydroxychloroquine in Treatment of Patients With Moderate COVID-19. J Zhejiang Univ (Med Sci).49(2), 215-9.
- 27. Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, Zhuang R, Hu B, Zhang Z, 2020. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv.7, DOI: 10.1101/2020.03.22.20040758.
- 28. Chong VH, Chong PL, Metussin D, Asli R, Momin RN, Mani BI, Abdullah MS. Conduction abnormalities in hydroxychloroquine add on therapy to lopinavir/ritonavir in COVID-19. J Med Virol. DOI: 10.1002/jmv.26004
- 10.1002/jmv.26004..
- 29. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Sevestre J, Mailhe M, Doudier B, Aubry C, Amrane S, et al., 2020. Clinical and microbiological effect of a combination of


- hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Medicine and Infectious Disease.34, DOI: 10.1016/j.tmaid.2020.101663.
- 30. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, Labella A, Manson DK, Kubin C, Barr RG, et al., 2020. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. New England Journal of Medicine.382(25), 2411-8 DOI: 10.1056/NEJMoa2012410.
- 31. Gérard A, Romani S, Fresse A, Viard D, Parassol N, Granvuillemin A, Chouchana L, Rocher F, Drici MD. "Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. Therapie. DOI: 10.1016/j.therap.2020.05.002
- 10.1016/j.therap.2020.05.002..
- 32. Hraiech S, Bourenne J, Kuteifan K, Helms J, Carvelli J, Gainnier M, Meziani F, Papazian L, 2020. Lack of viral clearance by the combination of hydroxychloroquine and azithromycin or lopinavir and ritonavir in SARS-CoV-2-related acute respiratory distress syndrome. Annals of Intensive Care.10(1), 1-3.
- 33. Macias J, Gonzalez-Moreno P, Sanchez-Garcia E, Morillo-Verdugo R, Dominguez-Quesada C, Pinilla A, Macho M, Martinez M, Gonzalez-Serna A, Corma A, 2020. Similar incidence of Coronavirus Disease 2019 (COVID-19) in patients with rheumatic diseases with and without hydroxychloroquine therapy. medRxiv.
- 34. Mahévas M, Tran VT, Roumier M, Chabrol A, Paule R, Guillaud C, Fois E, Lepeule R, Szwebel TA, Lescure FX, et al., 2020. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: Observational comparative study using routine care data. The BMJ.369, DOI: 10.1136/bmj.m1844.
- 35. Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, Weinberg P, Kirkwood J, Muse A, DeHovitz J, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. Jama. DOI: 10.1001/jama.2020.8630 10.1001/jama.2020.8630.
- 36. Stroppa EM, Toscani I, Citterio C, Anselmi E, Zaffignani E, Codeluppi M, Cavanna L. Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy). Future Oncol. DOI: 10.2217/fon-2020-0369 10.2217/fon-2020-0369.
- 37. van den Broek MPH, Möhlmann JE, Abeln BGS, Liebregts M, van Dijk VF, van de Garde EMW, 2020. Chloroquine-induced QTc prolongation in COVID-19 patients. Neth Heart J. 1-4 DOI: 10.1007/s12471-020-01429-7
- 10.1007/s12471-020-01429-7..
- 38. Voisin O, Lorc'h E, Mahé A, Azria P, Borie MF, Hubert S, Ménage E, Guillerm JC, Mourad JJ. ACUTE QT INTERVAL MODIFICATIONS DURING HYDROXYCHLOROQUINE-AZITHROMYCIN TREATMENT IN THE CONTEXT OF COVID-19 INFECTION. Mayo Clin Proc. DOI: 10.1016/j.mayocp.2020.05.005
- 10.1016/j.mayocp.2020.05.005..
- 39. Yu B, Li C, Chen P, Zhou N, Wang L, Li J, Jiang H, Wang DW, 2020. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Science China Life sciences. DOI: 10.1007/s11427-020-1732-2.

- 40. Huang M, Tang T, Pang P, Li M, Ma R, Lu J, Shu J, You Y, Chen B, Liang J, et al., 2020. Treating COVID-19 with Chloroquine. J Mol Cell Biol.12(4), 322-5 DOI: 10.1093/jmcb/mjaa014 10.1093/jmcb/mjaa014.
- 41. Magagnoli J, Narendran S, Pereira F, Cummings TH, Hardin JW, Sutton SS, Ambati J, 2020. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. Med.
- 42. Ramireddy A, Chugh HS, Reinier K, Ebinger J, Park E, Thompson M, Cingolani E, Cheng S, Marban E, Albert C, 2020. Experience with hydroxychloroquine and azithromycin in the COVID-19 pandemic: implications for QT interval monitoring. MedRxiv.
- 43. Barbosa J, Kaitis D, Freedman R, Le K, Lin X, 2020. Clinical outcomes of hydroxychloroquine in hospitalized patients with COVID-19: a quasi-randomized comparative study. N Engl J Med.
- 44. Mallat J, Hamed F, Balkis M, Mohamed MA, Mooty M, Malik A, Nusair A, Bonilla F, 2020. Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: A retrospective study. medRxiv.
- 45. Feng Z, Li J, Yao S, Yu Q, Zhou W, Mao X, Li H, Kang W, Ouyang X, Mei J, 2020. The Use of Adjuvant Therapy in Preventing Progression to Severe Pneumonia in Patients with Coronavirus Disease 2019: A Multicenter Data Analysis. medRxiv.
- 46. Mathian A, Mahevas M, Rohmer J, Roumier M, Cohen-Aubart F, Amador-Borrero B, Barrelet A, Chauvet C, Chazal T, Delahousse M, et al., 2020. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis.79(6), 837-9.
- 47. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, Wu Y, Xiao W, Liu S, Chen E, 2020. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. bmj.369.
- 48. Carlucci P, Ahuja T, Petrilli CM, Rajagopalan H, Jones S, Rahimian J, 2020. Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients. medRxiv.
- 49. Singh S, Khan A, Chowdhry M, Chatterjee A, 2020. Outcomes of Hydroxychloroquine Treatment Among Hospitalized COVID-19 Patients in the United States-Real-World Evidence From a Federated Electronic Medical Record Network. medRxiv.
- 50. Regina J, Papadimitriou-Olivgeris M, Burger R, Filippidis P, Tschopp J, Desgranges F, Viala B, Kampouri E, Rochat L, Haefliger D, 2020. Epidemiology, risk factors and clinical course of SARS-CoV-2 infected patients in a Swiss university hospital: an observational retrospective study.
- 51. de Novales FJM, Ramírez-Olivencia G, Estébanez M, de Dios B, Herrero MD, Mata T, Borobia AM, Gutiérrez C, Simón M, Ochoa A, 2020. Early hydroxychloroquine is associated with an increase of survival in COVID-19 patients: an observational study.
- 52. Lee JE, Lee SO, Heo J, Kim DW, Park MR, Son H, Kim D, Kim K-H, Lee S, Lee SH, 2020. Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of coronavirus disease 2019 with mild to moderate severity.
- 53. Million M, Lagier J-C, Gautret P, Colson P, Fournier P-E, Amrane S, Hocquart M, Mailhe M, Esteves-Vieira V, Doudier B, 2020. Full-length title: Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel medicine and infectious disease. 101738.


- 54. Okour M, Al-Kofahi M, Austin D, 2020. Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome. Journal of pharmacokinetics and pharmacodynamics. 1.
- 55. Saleh M, Gabriels J, Chang D, Kim BS, Mansoor A, Mahmood E, Makker P, Ismail H, Goldner B, Willner J, 2020. The effect of chloroquine, hydroxychloroquine and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection. Circulation: Arrhythmia and Electrophysiology.
- 56. Chorin E, Wadhwani L, Magnani S, Dai M, Shulman E, Nadeau-Routhier C, Knotts R, Bar-Cohen R, Kogan E, Barbhaiya C, 2020. QT interval prolongation and torsade De pointes in patients with COVID-19 treated with Hydroxychloroquine/azithromycin. Heart rhythm.
- 57. Chang D, Saleh M, Gabriels J, Ismail H, Goldner B, Willner J, Beldner S, Mitra R, John R, Epstein LM, 2020. Inpatient Use of Ambulatory Telemetry Monitors for COVID-19 Patients Treated with Hydroxychloroquine and/or Azithromycin. Journal of the American College of Cardiology. DOI: 10.1016/j.jacc.2020.04.032.
- 58. The General Hospital Corporation. ARS-CoV-2 INFECTION STATUSES AND RESOLUTIONCOVID-19, CoV-Presumed, CoV-Risk, and CoV-Exposed. 2020.
- 59. O'Laughlin JP, Mehta PH, Wong BC, 2016. Life Threatening Severe QTc Prolongation in Patient with Systemic Lupus Erythematosus due to Hydroxychloroquine. Case Rep Cardiol.2016, 4626279 DOI: 10.1155/2016/4626279.
- 60. Shamshirian A, Hessami A, Heydari K, Alizadeh-Navaei R, Ebrahimzadeh MA, George WY, Ghasemian R, Sedaghat M, Baradaran H, Yazdi SM, 2020. Hydroxychloroquine Versus COVID-19: A Periodic Systematic Review and Meta-Analysis. MedRxiv.











		HCQ		Stan	dard ca	are	1	Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
B.Yu, 2020	15.33	8.41	48	8.67	7.43	502	23.2%	0.88 [0.58, 1.19]	-
ES. Rosenberg, 2020	7.67	5.94	198	4.33	3.72	395	25.8%	0.73 [0.55, 0.90]	-
J.Magagnoli, 2020	7.67	5.96	271	4	4.48	221	25.7%	0.69 [0.50, 0.87]	
M.Huang, 2020	19.33	5.23	197	19.33	6.13	176	25.3%	0.00 [-0.20, 0.20]	<u>†</u>
Total (95% CI)	42: Ob:	e 20 (714		0000		100.0%	0.57 [0.20, 0.94]	•
Heterogeneity: $Tau^2 = 0$. Test for overall effect: Z :				3 (P < U	1.00001	i); i*= 9	12%	•	-4 -2 0 2 4 Favours [HCQ+AZM] Favours [Standrd care]















	HCC	1	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
J.Mallat 2020	14	23	10	11	39.6%	0.67 [0.46, 0.98]	-
M.Huang 2020	189	197	140	176	0.0%	1.21 [1.11, 1.31]	
W.Tang 2020	60	75	61	75	60.4%	0.98 [0.84, 1.15]	-
Total (95% CI)		98		86	100.0%	0.84 [0.58, 1.22]	
Total events	74		71				
Heterogeneity: Tau ² =				P = 0.0	6); I= 71	%	0.1 0.2 0.5 1 2 5 10
Test for overall effect:	∠= 0.90 (P = 0.3	(1)				Favours [Standard Care] Favours [HCQ]

	HCC	HCQ Standard care			Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
J.Chen, 2020	13	15	14	15	33.9%	0.93 [0.73, 1.18]	-
J.Mallet, 2020	14	23	10	11	25.4%	0.67 [0.46, 0.98]	
P.Gautret, 2020	8	14	2	16	4.1%	4.57 [1.16, 18.05]	
W.Tang, 2020	53	75	56	75	36.6%	0.95 [0.78, 1.15]	•
Total (95% CI)		127		117	100.0%	0.92 [0.69, 1.23]	•
Total events	88		82				
Heterogeneity: Tau2 =	0.05; Chi	$i^2 = 9.03$	3, df = 3 (P)	= 0.03);	I= 67%		0.01 0.1 1 10 100
Test for overall effect:	Z = 0.56	(P = 0.5)	i7)				Favours [HCQ] Favours [Standard care]







	HCC	Q	Standared	care		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
ES. Rosenberg, 2020	27	221	52	271	39.3%	0.64 [0.41, 0.98]	
J.Chen, 2020	0	15	1	15	13.0%	0.33 [0.01, 7.58]	-
M.Huang, 2020	6	157	1	184	20.7%	7.03 [0.86, 57.78]	
W.Tang, 2020	0	80	1	70	12.6%	0.29 [0.01, 7.06]	-
Z.Chen, 2020	4	31	0	31	14.4%	9.00 [0.51, 160.39]	-
Total (95% CI)	27	504	55	571	100.0%	1.28 [0.33, 4.99]	
Total events	37		55				
Heterogeneity: Tau ² = 1.	18; Chi²=	8.66, 0	df = 4 (P = 0.0	07); = =	54%		0.1 0.2 0.5 1 2 5 10
Test for overall effect: Z =	= 0.35 (P	= 0.72)					Favours [HCQ] Favours [Standared care]


	HCC	2	Standard	care		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
ES. Rosenberg, 2020	31	268	7	221	23.1%	3.65 [1.64, 8.13]	
J.Barbosa, 2020	7	17	2	21	13.1%	4.32 [1.03, 18.17]	-
J.Magagnoli, 2020	34	179	90	452	32.1%	0.95 [0.67, 1.36]	-
J.Mallet, 2020	0	21	0	13		Not estimable	
S.Singh,2020	46	910	57	910	31.7%	0.81 [0.55, 1.18]	 +
T-4-1 (05% CI)		4205		4047	400.00	4 50 50 70 2 001	
Total (95% CI)		1395		1617	100.0%	1.50 [0.78, 2.89]	
Total events	118		156				
Heterogeneity: Tau ² = 0.3	31; Chi ² =	= 15.39	, df = 3 (P =	: 0.002)	; I= 81%		0.01 0.1 1 10 100
Test for overall effect: Z =	= 1.22 (P	= 0.22)					Favours [HCQ] Favours [Standard care]


	HCC	2	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
ES.Rosenberg 2020	31	268	7	221	0.0%	3.65 [1.64, 8.13]	
J. Magagnoli 2020	7	17	2	21	9.6%	4.32 [1.03, 18.17]	
J.Barbosa 2020	34	179	90	452	46.0%	0.95 [0.67, 1.36]	+
J.Mallat 2020	0	21	0	13		Not estimable	
S.Singh 2020	45	910	57	910	44.4%	0.79 [0.54, 1.15]	
Total (95% CI)		1127		1396	100.0%	1.01 [0.62, 1.65]	
	06	1121	4.40	1390	100.070	1.01 [0.02, 1.03]	—
Total events	86		149				
Heterogeneity: Tau ² = 0	1.10; Chi²	= 5.13,	df = 2 (P	= 0.08); l³ = 61%	6	0.04 0.4 40 400
Test for overall effect: Z	= 0.06 (F	P = 0.95	i)				0.01 0.1 1 10 100 Favours [HCQ] Favours [Standard Care]
							ravours [mod] ravours (standard date)



	HCC)	Standard	care		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
B.Yu, 2020	9	48	238	502	14.8%	0.40 [0.22, 0.72]	
ES. Rosenberg, 2020	54	271	28	221	16.8%	1.57 [1.03, 2.39]	
FJ.Membrillo, 2020	27	123	21	43	16.4%	0.45 [0.29, 0.71]	
J.Barbosa, 2020	2	17	1	21	3.5%	2.47 [0.24, 24.98]	
J.Magagnoli, 2020	38	198	37	395	16.8%	2.05 [1.35, 3.12]	
M.Mahévas, 2020	9	84	8	89	11.4%	1.19 [0.48, 2.94]	-
P.Gautret, 2020	1	20	0	16	2.0%	2.43 [0.11, 55.89]	
S.Singh,2020	104	910	109	910	18.3%	0.95 [0.74, 1.23]	
Total (95% CI)		1671		2197	100.0%	0.99 [0.61, 1.59]	
Total events	244		442				
Heterogeneity: Tau ² = 0.	30; Chi ² =	38.18	df = 7 (P <	0.0000	1); I= 82	2%	0.1 0.2 0.5 1 2 5 10
Test for overall effect: Z =	= 0.05 (P	= 0.96)					Favours [HCQ] Favours [Standrad care]







	HCQ+AZM Standared care			Risk Ratio	Risk Ratio		
Study or Subgroup	Events Total		Events	Total	Weight	M-H, Random, 95% CI	CI M-H, Random, 95% CI
ES.Rosenberg, 2020	94	733	7	221	18.4%	4.05 [1.91, 8.60]	n ——
J.Magagnoli, 2020	36	176	90	452	26.8%	1.03 [0.73, 1.45]	· ·
S.Hraiech, 2020	16	17	15	15	29.5%	0.95 [0.80, 1.12]	2) +
s.signh	40	701	41	701	25.3%	0.98 [0.64, 1.49]) -
Total (95% CI)		1627		1389	100.0%	1.27 [0.76, 2.13]	
Total events	186		153				
Heterogeneity: Tau ² = 0	.23; Chi ² :	= 24.47	, df = 3 (P <	0.0001)	; I= 88%		0.01 0.1 1 10 100
Test for overall effect: Z	= 0.92 (P	= 0.36))				0.01 0.1 1 10 100 Favours [HCQ+AZM] Favours [Standared care]

	HCQ+	AZ	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
ES.Rosenberg 2020	94	733	7	221		Not estimable	
J. Magagnoli 2020	36	176	90	452	16.5%	1.03 [0.73, 1.45]	<u>+</u>
S.Hraiech 2020	16	17	15	15	72.5%	0.95 [0.80, 1.12]	
S.Singh 2020	40	701	41	701	11.0%	0.98 [0.64, 1.49]	+
Total (95% CI) Total events	92	894	146	1168	100.0%	0.96 [0.84, 1.11]	•
Heterogeneity: Tau ² = 0		= 0.40.		= 0.82): I= 0%		
Test for overall effect: Z					,,,		0.01 0.1 1 10 100 Favours [HCQ+AZ] Favours [Standard Care]

	AZM+HCQ Standard care			Risk Ratio	Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI	
ES. Rosenberg, 2020	189	735	28	221	32.0%	2.03 [1.41, 2.93]		
J.Magagnoli, 2020	49	214	37	395	31.0%	2.44 [1.65, 3.62]		
S.Hraiech, 2020	2	17	0	15	2.0%	4.44 [0.23, 85.83]	-	
S.Singh,2020	86	701	72	701	35.0%	1.19 [0.89, 1.60]	-	
Total (95% CI)		1667		1332	100.0%	1.81 [1.19, 2.77]		
Total events	326		137					
Heterogeneity: Tau ² = 0.	11; Chi²=	10.06	df = 3 (P =	0.02); 1	== 70%		0.2 0.5 1 2 5	
Test for overall effect: Z =	= 2.75 (P =	= 0.006	5)				Favours [HCQ+AZM] Favours [Standard care]	

	HCQ+	AZ	Control			Risk Ratio	Risk Ratio
Study or Subgroup	Events	events Total Events Total		Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
ES.Rosenberg 2020	189	735	28	221	53.0%	2.03 [1.41, 2.93]	-
J. Magagnoli 2020	49	214	37	395	46.2%	2.44 [1.65, 3.62]	-
S.Hraiech 2020	2	17	0	15	0.8%	4.44 [0.23, 85.83]	-
S.Singh 2020	86	701	72	701		Not estimable	
Total (95% CI)		966		631	100.0%	2.23 [1.70, 2.91]	•
Total events	240		65				
Heterogeneity: Tau ² = 0	0.00; Chi ²	= 0.68,	df = 2 (P	= 0.71); I= 0%		0.01 0.1 1 10 100
Test for overall effect: Z	= 5.87 (F	o.000	1001)				0.01 0.1 1 10 100 Favours [HCQ+AZ] Favours [Standard Care]

		HCQ		C	ontrol			Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
B.Yu 2020	15.33	8.41	48	8.67	7.43	502	23.2%	0.88 [0.58, 1.19]	
ES.Rosenberg 2020	7.67	5.94	198	4.33	3.72	395	25.8%	0.73 [0.55, 0.90]	•
J. Magagnoli 2020	7.67	5.96	271	4	4.48	221	25.7%	0.69 [0.50, 0.87]	•
M.Huang, 2020	19.33	5.23	197	19.33	6.13	176	25.3%	0.00 [-0.20, 0.20]	•
Total (95% CI)			714			1294	100.0%	0.57 [0.20, 0.94]	◆
Heterogeneity: Tau² = Test for overall effect: :			V 30-30-70	= 3 (P <	0.000	01); I²=	92%	後 日	-4 -2 0 2 4 Favours [HCQ] Favours [Standard care]

	HCQ		Control		Risk Ratio		Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, Rand	om, 95% CI	
J.Chen 2020	13	15	14	15	35.7%	0.93 [0.73, 1.18]		-	-	
J.Mallat 2020	14	23	10	11	17.4%	0.67 [0.46, 0.98]				
P.Gautret 2020	8	14	2	16	0.0%	4.57 [1.16, 18.05]				
W.Tang 2020	53	75	56	75	46.9%	0.95 [0.78, 1.15]		•		
Total (95% CI)		113		101	100.0%	0.89 [0.75, 1.05]		•		
Total events	80		80							
Heterogeneity: Tau ² = 0.01; Chi ² = 2.68, df = 2 (P = 0.26); I ² = 25%							0.01	01	10	100
Test for overall effect: $Z = 1.41$ (P = 0.16)							0.01 Favours	0.1 [Standard Care]	Favours [HCQ]	100